Hepatorenal Syndrome

Clinics in Liver Disease

Volumn 10, Issue 2, 2006, Pages 371-385

  Cárdenas, Andrés ^a   Gines, Pere ^a  

^a HOSPITAL CLÍNIC   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; MIDODRINE; NORADRENALIN; OCTREOTIDE; ORNIPRESSIN; PENTOXIFYLLINE; PLASMA SUBSTITUTE; SOMATOSTATIN DERIVATIVE; TERLIPRESSIN; VASOACTIVE AGENT; VASOCONSTRICTOR AGENT; VASOPRESSIN;

ALCOHOL LIVER DISEASE; BLOOD PRESSURE; BLOOD VOLUME; CLINICAL FEATURE; DIALYSIS; DRUG INFUSION; FEASIBILITY STUDY; HEART OUTPUT; HEPATORENAL SYNDROME; HUMAN; HYPOKINESIA; ISCHEMIA; KIDNEY FAILURE; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; PATHOGENESIS; REVIEW; SPLANCHNIC BLOOD FLOW; TREATMENT INDICATION; VASOCONSTRICTION; VASODILATATION; VENOUS RETURN;

HEPATORENAL SYNDROME; HUMANS; LIVER TRANSPLANTATION; PORTASYSTEMIC SHUNT, SURGICAL; RENAL DIALYSIS; VASOCONSTRICTOR AGENTS;

EID: 33846235194     PISSN: 10893261     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cld.2006.05.006     Document Type: Review

References (60)

1. Arroyo V., Ginès P., Gerbes A., et al. Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. Hepatology 23 (1996) 164-176
2. Ginès P., Cárdenas A., Arroyo V., et al. Management of cirrhosis and ascites. N Engl J Med 350 (2004) 1646-1654
3. Akriviadis E., Botla R., Briggs W., et al. Pentoxifylline improves short-term survival in severe acute alcoholic hepatitis: a double-blind, placebo-controlled trial. Gastroenterology 119 (2000) 1637-1648
4. Moore K. Renal failure in acute liver failure. Eur J Gastroenterol Hepatol 11 (1999) 967-975
5. Ginès A., Escorsell A., Ginès P., et al. Incidence, predictive factors, and prognosis of hepatorenal syndrome in cirrhosis. Gastroenterology 105 (1993) 229-236
6. Alessandria C., Ozdogan O., Guevara M., et al. MELD score and clinical type predict prognosis in hepatorenal syndrome: relevance to liver transplantation. Hepatology 41 (2005) 1282-1289
7. Sort P., Navasa M., Arroyo V., et al. Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis. N Engl J Med 5 (1999) 403-409
8. Moreau R., and Lebrec D. Hepatorenal syndrome-definitions and diagnosis. Aliment Pharmacol Ther 20 Suppl 3 (2004) 24-28
9. Schrier R.W., Arroyo V., Bernardi M., et al. Peripheral arterial vasodilation hypothesis: a proposal for the initiation of renal sodium and water retention in cirrhosis. Hepatology 8 (1988) 1151-1157
10. Iwakiri Y., and Groszmann R. The hyperdynamic circulation of chronic liver diseases: from the patient to the molecule. Hepatology 43 (2006) S121-S131
11. Bernardi M., and Domenicali M. The renin-angiotensin-aldosterone system in cirrhosis. In: Ginès P., Arroyo V., Rodés J., et al. (Eds). Ascites and renal dysfunction in liver disease (2005), Blackwell Publishing, Oxford (UK) 43-53
12. Dudley F., and Esler M. The sympathetic nervous system in cirrhosis. In: Ginès P., Arroyo V., Rodés J., et al. (Eds). Ascites and renal dysfunction in liver disease (2005), Blackwell Publishing, Oxford (UK) 54-72
13. Ishikawa S., and Schrier R.W. Pathophysiological roles of arginine vasopressin and aquaporin-2 in impaired water excretion. Clin Endocrinol (Oxf) 58 (2003) 1-17
14. Arroyo V., and Colmenero J. Ascites and hepatorenal syndrome in cirrhosis: pathophysiological basis of therapy and current management. J Hepatol 38 Suppl 1 (2003) S69-S89
15. Terra C., Guevara M., Torre A., et al. Renal failure in patients with cirrhosis and sepsis unrelated to spontaneous bacterial peritonitis. Value of MELD score. Gastroenterology 129 (2005) 1944-1953
16. Ruiz del Arbol L., Monescillo A., Arocena C., et al. Circulatory function and hepatorenal syndrome in cirrhosis. Hepatology 42 (2005) 439-447
17. Ruiz-del-Arbol W., Urman J., Fernandez J., et al. Systemic, renal, and hepatic hemodynamic derangement in cirrhotic patients with spontaneous bacterial peritonitis. Hepatology 38 (2003) 1210-1218
18. Cárdenas A., and Ginès P. Management of hyponatremia in cirrhosis. In: Ginès P., Arroyo V., Rodés J., et al. (Eds). Ascites and renal dysfunction in liver disease (2005), Blackwell Publishing, Oxford (UK) 305-314
19. Caregaro L., Menon F., Angeli P., et al. Limitations of serum creatinine level and creatinine clearance as filtration markers in cirrhosis. Arch Intern Med 154 (1994) 201-205
20. Sherman D., Fish D.N., and Teitelbaum I. Assessing renal function in cirrhotic patients: problems and pitfalls. Am J Kidney Dis 41 (2003) 269-278
21. Cárdenas A. Hepatorenal syndrome: a dreaded complication of end-stage liver disease. Am J Gastroenterol 100 (2005) 1-8
22. Ginès P., Titó L., Arroyo V., et al. Randomized comparative study of therapeutic paracentesis with and without intravenous albumin in cirrhosis. Gastroenterology 94 (1988) 1493-1502
23. Follo A., Llovet J.M., Navasa M., et al. Renal impairment after spontaneous bacterial peritonitis in cirrhosis: incidence, clinical course, predictive factors and prognosis. Hepatology 20 (1994) 1495-1501
24. Cárdenas A., Ginès P., Uriz J., et al. Renal failure after upper gastrointestinal bleeding in cirrhosis. Incidence, clinical course, predictive factors and short-term prognosis. Hepatology 34 (2001) 671-676
25. Guevara M., Fernandez-Esparrach G., Alessandra C., et al. Effects of contrast media on renal function in patients with cirrhosis: a prospective study. Hepatology 40 (2004) 646-651
26. Watt K., Uhanova J., and Minuk G.Y. Hepatorenal syndrome: diagnostic accuracy, clinical features, and outcome in a tertiary care center. Am J Gastroenterol 97 (2002) 2046-2050
27. Servin-Abad L., Regev A., Contreras G., et al. Retrospective analysis of 140 patients labeled as hepatorenal syndrome in a referral center. Hepatology 42 (2005) 543A
28. Guevara M., Ginès P., Fernandez-Esparrach G., et al. Reversibility of hepatorenal syndrome by prolonged administration of ornipressin and plasma volume expansion. Hepatology 27 (1998) 35-41
29. Gulberg V., Bilzer M., and Gerbes A.L. Long-term therapy and retreatment of hepatorenal syndrome type 1 with ornipressin and dopamine. Hepatology 30 (1999) 870-875
30. Hadengue A., Gadano A., Moreau R., et al. Beneficial effects of the 2-day administration of terlipressin in patients with cirrhosis and hepatorenal syndrome. J Hepatol 29 (1998) 565-570
31. Uriz J., Ginès P., Cárdenas A., et al. Terlipressin plus albumin infusion: an effective and safe therapy of hepatorenal syndrome. J Hepatol 33 (2000) 43-48
32. Mulkay J.P., Louis H., Donckier V., et al. Long-term terlipressin administration improves renal function in cirrhotic patients with type 1 hepatorenal syndrome: a pilot study. Acta Gastroenterol Belg 64 (2001) 15-19
33. Moreau R., Durand F., Poynard T., et al. Terlipressin in patients with cirrhosis and type 1 hepatorenal syndrome: a retrospective multicenter study. Gastroenterology 122 (2002) 923-930
34. Alessandria C., Venon W.D., Marzano A., et al. Renal failure in cirrhotic patients: role of terlipressin in clinical approach to hepatorenal syndrome type 2. Eur J Gastroenterol Hepatol 14 (2002) 1363-1368
35. Ortega R., Ginès P., Uriz J., et al. Terlipressin therapy with and without albumin for patients with hepatorenal syndrome. Results of a prospective, non-randomized study. Hepatology 36 (2002) 941-948
36. Halimi C., Bonnard P., Bernard B., et al. Effect of terlipressin (Glypressin) on hepatorenal syndrome in cirrhotic patients: results of a multicentre pilot study. Eur J Gastroenterol Hepatol 14 (2002) 153-158
37. Colle I., Durand F., Pessione F., et al. Clinical course, predictive factors and prognosis in patients with cirrhosis and type 1 hepatorenal syndrome treated with Terlipressin: a retrospective analysis. J Gastroenterol Hepatol 17 (2002) 882-888
38. Solanki P., Chawla A., Garg R., et al. Beneficial effects of terlipressin in hepatorenal syndrome: a prospective, randomized placebo-controlled clinical trial. J Gastroenterol Hepatol 18 (2003) 152-156
39. Saner F., Kavuk I., Lang H., et al. Terlipressin and gelafundin: safe therapy of hepatorenal syndrome. Eur J Med Res 9 (2004) 78-82
40. Saner F.H., Fruhauf N.R., Schafers R.F., et al. Terlipressin plus hydroxyethyl starch infusion: an effective treatment for hepatorenal syndrome. Eur J Gastroenterol Hepatol 15 (2003) 925-927
41. Gluud L.L., Kjaer M., Taastroem, et al. Terlipressin for hepatorenal syndrome: a Cochrane systematic review. J Hepatol 42 (2005) 206A
42. Angeli P., Volpin R., Gerunda G., et al. Reversal of type 1 hepatorenal syndrome with the administration of midodrine and octreotide. Hepatology 29 (1999) 1690-1697
43. Wong F., Pantea L., and Sniderman K. Midodrine, octreotide, albumin, and TIPS in selected patients with cirrhosis and type 1 hepatorenal syndrome. Hepatology 40 (2004) 55-64
44. Duvoux C., Zanditenas D., Hezode C., et al. Effects of noradrenaline and albumin in patients with type 1 hepatorenal syndrome: a pilot study. Hepatology 36 (2002) 374-380
45. Kiser T.H., Fish D.N., Obritsch M.D., et al. Vasopressin, not octreotide, may be beneficial in the treatment of hepatorenal syndrome: a retrospective study. Nephrol Dial Transplant 20 (2005) 1813-1820
46. Arroyo V., Terra C., Torre A., et al. Hepatorenal syndrome in cirrhosis: clinical features, diagnosis, and management. In: Ginès P., Arroyo V., Rodés J., et al. (Eds). Ascites and renal dysfunction in liver disease (2005), Blackwell Publishing, Oxford (UK) 341-359
47. Arroyo V., Ruiz del Arbol, and Ginés P. Circulatory dysfunction in cirrhosis. In: Arroyo V., Navasa M., Forns X., et al. (Eds). Update in treatment of liver disease (2005), Ars Medica, Barcelona (Spain) 19-28
48. Pomier-Layrargues G., Paquin S.C., Hassoun Z., et al. Octreotide in hepatorenal syndrome: a randomized, double-blind, placebo-controlled, crossover study. Hepatology 38 (2003) 238-243
49. Restuccia T., Ortega R., Guevara M., et al. Effects of treatment of hepatorenal syndrome before transplantation on posttransplantation outcome. A case-control study. J Hepatol 40 (2004) 140-146
50. Guevara M., Ginès P., Bandi J.C., et al. Transjugular intrahepatic portosystemic shunt in hepatorenal syndrome: effects on renal function and vasoactive systems. Hepatology 28 (1998) 416-422
51. Brensing K.A., Textor J., Perz J., et al. Long-term outcome after transjugular intrahepatic portosystemic stent-shunt in non-transplant cirrhotics with hepatorenal syndrome: a phase II study. Gut 47 (2000) 288-295
52. Testino G., Ferro C., Sumberaz A., et al. Type-2 hepatorenal syndrome and refractory ascites: role of transjugular intrahepatic portosystemic stent-shunt in eighteen patients with advanced cirrhosis awaiting orthotopic liver transplantation. Hepatogastroenterology 50 (2003) 1753-1755
53. Kapling R.K., and Bastani B. The clinical course of patients with type 1 hepatorenal syndrome maintained on hemodialysis. Ren Fail 26 (2004) 563-568
54. Keller F., Heinze H., Jochimsen F., et al. Risk factors and outcome of 107 patients with decompensated liver disease and acute renal failure (including 26 patients with hepatorenal syndrome): the role of hemodialysis. Ren Fail 17 (1995) 135-146
55. Mitzer S.R., Stange J., Klammt S., et al. Improvement of hepatorenal syndrome with extracorporeal albumin dialysis MARS: results of a prospective, randomized, controlled clinical trial. Liver Transpl 6 (2000) 277-286
56. Rifai K., Ernst T., Kretschmer U., et al. The Prometheus device for extracorporeal support of combined liver and renal failure. Blood Purif 23 (2005) 298-302
57. Rimola A., Navasa M., Grande L., et al. Liver transplantation for patients with cirrhosis and ascites. In: Ginès P., Arroyo V., Rodés J., et al. (Eds). Ascites and renal dysfunction in liver disease (2005), Blackwell Publishing, Oxford (UK) 271-285
58. Cárdenas A., and Ginès P. Management of complications of cirrhosis in patients awaiting liver transplantation. J Hepatol 42 (2005) S124-S133
59. Campbell M.S., Kotlyar D.S., Brensinger C.M., et al. Renal function after orthotopic liver transplantation is predicted by duration of pretransplantation creatinine elevation. Liver Transpl 11 (2005) 1048-1055
60. Fernandez J., Monteagudo J., Bargallo X., et al. A randomized unblinded pilot study comparing albumin versus hydroxyethyl starch in spontaneous bacterial peritonitis. Hepatology 42 (2005) 627-634